MinorSelective serotonin reuptake inhibitors (SSRIs)×Estrogens – natural and semisynthetic
Updated · Methodology
Mechanism
CYP3A4 partly metabolises estradiol. Strong and moderate inhibitors of this enzyme, such as azole antifungals, verapamil, macrolides and diltiazem, can raise oestrogen levels. Drugs that induce cytochrome P450 enzymes can speed up oestrogen metabolism (Progynova SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; estradiol tablets label, US Food and Drug Administration, FDA). Escitalopram inhibits a different enzyme, CYP2D6, and weakly CYP2C19 (Cipralex SmPC, AEMPS). In vitro, it did not inhibit CYP3A4, interaction studies at 20 mg showed no CYP3A4 inhibition, and its documents do not describe it as an enzyme inducer (Lexapro label, FDA). CYP2C19, CYP3A4 and CYP2D6 metabolise escitalopram, but even ritonavir, a strong CYP3A4 inhibitor, did not significantly change its pharmacokinetics (Cipralex SmPC, AEMPS; Lexapro label, FDA). The documents do not describe estradiol as an enzyme inhibitor or inducer.
Symptoms
The documents describe no symptoms linked to this combination. Each drug keeps its own adverse effects. The most frequent adverse effects of escitalopram are headache and nausea, and insomnia, drowsiness, dizziness, diarrhoea and increased sweating are common (Cipralex SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The adverse effects of estradiol in hormone replacement therapy include weight change, depressed mood, headache, abdominal pain, nausea, rash and itching, uterine or vaginal bleeding including spotting, breast pain and oedema (Progynova SmPC, AEMPS).
Management
According to the documents, the combination is acceptable, and the doses of escitalopram and estradiol need no change. No document names the pair. The estradiol SmPC gives azole antifungals, verapamil, macrolides, diltiazem and grapefruit juice as examples of CYP3A4 inhibitors that can raise oestrogen levels. Escitalopram is not on this list (Progynova SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to interaction studies in the US label, escitalopram 20 mg has no CYP3A4 inhibitory effect (Lexapro label, US Food and Drug Administration, FDA). In women with diabetes on hormone replacement therapy, the need for oral antidiabetic drugs or insulin may change in individual cases (Progynova SmPC, AEMPS). In patients with diabetes, escitalopram can push blood glucose either way, and the dose of insulin or oral antidiabetic drugs may need adjusting (Cipralex SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Lexapro (escitalopram) prescribing information (2023)– FDA label, Allergan, Inc., DailyMed setid 13bb8267-1cab-43e5-acae-55a4d957630a, revised 10/2023, sections 4, 5.2 and 7
- AEMPS: Ficha técnica de Cipralex 10 mg (escitalopram) (2026)– AEMPS CIMA, nregistro 65230, revisión 03/2026, secciones 4.3 y 4.5
- AEMPS: Ficha técnica: Estradiol (nº registro 47814), sección 4.5 (2026)– AEMPS, CIMA, nº registro 47814, revisión 02/2026, sección 4.5
- FDA: Estradiol tablets, Teva (estradiol) prescribing information (2024)– FDA, DailyMed setid c4936878-1643-4e7f-9b0d-e4957935aef2 (Teva Pharmaceuticals USA), revisión 02/2024 (versión 16), CLINICAL PHARMACOLOGY (Drug Interactions), PRECAUTIONS (Fluid retention, Exacerbation of other conditions)